Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, hereditary disease	Active, not recruiting	Phase 1 / Phase 2	2025-04-01		NCT06314490

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
California Institute for Regenerative Medicine (CIRM)	36
n-Lorem Foundation	18
University of California, San Diego	337

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Rady Children's Hospital	San Diego	United States	52

Clinical trials